3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
1
Liver Neoplasms
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Carcinoma, Hepatocellular
1
Interventions
durvalumab
18
Bevacizumab
17
atezolizumab
13
lenvatinib
10
Magnetic Resonance Spectroscopy
10
tremelimumab
8
Nivolumab
8
pembrolizumab
7
Sorafenib
6
Specimen Handling
5
camrelizumab
4
cabozantinib
4
Immunoglobulin G
4
Disulfides
4
sintilimab
3
apatinib
3
X-Rays
3
Radiotherapy
3
Radiofrequency Ablation
3
Radiation
3
Hepatectomy
3
E-7386
3
Doxorubicin
3
Cyclophosphamide
3
tislelizumab
2
relatlimab
2
dostarlimab
2
budigalimab
2
Standard of Care
2
Simvastatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Hepatocellular
×
Cell- and Tissue-Based Therapy
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled